araag2/HINT huggingface dataset:
Clinical trial NCT02548585 (phase 1/phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: medi0382, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of T2DM

          -  Must provide written informed consent

          -  Body mass index greater than (>) 27 and less than (<) 40 kg/m^2, inclusive

          -  Venous access suitable for multiple cannulations

          -  Vital signs within normal specified ranges

          -  Females must be non-lactating and non-childbearing potential

          -  Males must practice 2 effective contraceptive measures if sexually active

        Exclusion Criteria:

          -  Any concurrent condition that in the opinion of the investigator would interfere with
             the evaluation of the investigational product

          -  History or presence of gastrointestinal, renal, or hepatic disease or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs

          -  History of cancer within the last 10 years, with the exception of non-melanoma skin
             cancer

          -  Any clinically important illness (except for T2DM), medical/surgical procedure, or
             trauma within 4 weeks prior to dosing

          -  Fasting glucose greater than or equal to (>=) 200 mg/dL

          -  Positive Hepatitis B, Hepatitis C or human immunodeficiency virus test or use of
             antiretroviral medications at screening.

          -  Concurrent or previous use of a glucagon-like peptide 1 receptor agonist

          -  Current or previous use of systemic corticosteroids within the past 28 days prior to
             screening

          -  Use of any medicinal products or herbal preparations licensed for control of body
             weight or appetite is prohibited.

          -  Known or suspected history of alcohol or drug abuse within the past 3 years.

          -  Positive drug screen
Clinical trial NCT02548806 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: clonidine mbt 50µg, clonidine mbt 100µg, catapres 100μg
SMILES: ClC1=CC=CC(Cl)=C1NC1=NCCN1, ClC1=CC=CC(Cl)=C1NC1=NCCN1, ClC1=CC=CC(Cl)=C1NC1=NCCN1
Eligibility criteria:

        Main Inclusion Criteria:

          -  Healthy males or females (non-pregnant/non-lactating) aged 18 - 50 years.

          -  A Body Mass Index (BMI) of 18-30.

          -  No clinically significant abnormal serum biochemistry, haematology and urine
             examination values.

          -  A negative urinary drugs of abuse screen.

          -  Negative HIV and Hepatitis B and C results.

          -  No clinically significant abnormalities in 12-lead electrocardiogram (ECG).

          -  No clinically significant abnormalities in blood pressure or pulse.

          -  No allergy or sensitivity to clonidine or any of its excipients.

          -  No allergy to milk or milk derivatives.

          -  Subjects must provide written informed consent to participate in the study

        Main Exclusion Criteria:

          -  Current or past medical condition that might significantly affect the pharmacokinetic
             or

          -  pharmacodynamic response to clonidine.

          -  Participation in a New Chemical Entity clinical study within the previous 3 months or
             a marketed drug clinical study within the previous 30 days.

          -  Pathological condition of the oral cavity that would affect administration via the
             buccal route.

          -  Raynaud's disease or other peripheral vascular disease.

          -  Receipt of regular medication within 14 days of the first dose that may have an impact
             on the safety and objectives of the study (at the Investigator's discretion).

          -  Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or
             metabolic dysfunction.

          -  Symptomatic postural hypotension evident on screening

          -  History or evidence of Suicidal Ideation and/or behaviour as determined by using
             Columbia-Suicide Severity Rating Scale (C-SSRS)
Clinical trial NCT02550678 (phase 1/phase 2, status: completed)
Conditions: basal cell nevus syndrome, skin neoplasm, nodular basal cell carcinoma of skin
ICD codes: D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: 5-fu
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Low risk nodular basal cell carcinoma

          2. Biopsy of any other skin tumor

          3. Willingness to have injection therapy followed by surgery

          4. Written informed consent

        Exclusion Criteria:

          1. No or only minimal symptoms

          2. Known or suspected metastatic disease.

          3. Pregnant or Lactating females

          4. Clinically active or uncontrolled skin disease

          5. Immunocompromised or receiving immunomodulating agent

          6. treatment with psoralen plus Ultraviolet A or Ultraviolet B light therapy within 6
             months

          7. Any serious or active medical or psychiatric illness

          8. Recreational or therapeutic drug or alcohol use

          9. Taking any investigational product within 1 month of first dose of ASN- 002.
Clinical trial NCT02555007 (phase 1, status: unknown status)
Conditions: non small cell lung cancer (nsclc), malignant pleural mesothelioma (mpm)
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: vinorelbine
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients (male or female) ≥ 18 years of age.

          -  Patients with histologically documented, locally advanced or recurrent (stage IIIB) or
             metastatic (Stage IV) non-small cell lung Cancer or malignant pleural mesothelioma,
             for which no standard exits.

          -  Presence of at least one measurable lesion according to RECIST v.1.1 for NSCLC and
             modified RECIST 1.1 for MPM

          -  ECOG performance status ≤2

        Exclusion Criteria:

          -  ECOG performance status >2

          -  Patients with significant or uncontrolled cardiovascular disease (eg, congestive heart
             failure, angor, arrhythmia) within 6 months of starting study treatment

          -  Any neurological or psychiatric condition interfering with the understanding of study

          -  Infectious condition uncontrolled

          -  Any other medical condition that would jeopardize the subject participation
Clinical trial NCT02562313 (phase 1, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: biochaperone insulin lispro, humalog®
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes for at least 12 months

          -  Body Mass Index (BMI) between 18.5 and 28.5 kg/m^2, both inclusive

          -  Using or having used a Roche CSII system (Accu-Chek® Spirit Combo/ Accu- Chek® Spirit)
             for at least 6 months before screening. In Part B subjects using any form of CSII
             treatment for at least 6 months before screening will be included.

          -  HbA1c <= 9.0%.

          -  Total insulin dose of < 1.2 (I)U/kg/day

          -  Ability to calculate insulin bolus manually or using a bolus calculator and
             willingness to consume regular meals, perform carbohydrate counting, self-monitoring
             of plasma glucose (SMPG) profiles and use of Continuous Glucose Monitoring (CGM).

          -  Fasting C-peptide <= 0.30 nmol/L

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to Investigational Medicinal Product(s) (IMP(s))
             or related products

          -  Type 2 diabetes mellitus

          -  Previous participation in this trial.

          -  Receipt of any investigational product in a clinical trial within 60 days before
             randomisation in this trial

          -  Clinically significant abnormal haematology, biochemistry, urinalysis, or coagulation
             screening test

          -  Presence of clinically significant acute gastrointestinal symptoms

          -  Known slowing of gastric emptying and or gastrointestinal surgery

          -  Unusual meal habits and special dietary requirements or unwillingness to eat the food
             provided in the trial

          -  History of diabetic ketoacidosis (DKA) episodes requiring hospitalization within 6
             months prior to screening

          -  History of abscess at the infusion site within 6 months prior to screening

          -  Hypoglycaemia unawareness as judged by the Investigator

          -  History of severe hypoglycaemic episodes requiring hospitalization within the last 6
             months prior to screening
Clinical trial NCT02562326 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: biochaperone insulin lispro, humalog®
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus ≥ 12 months

          -  Treated with stable multiple daily insulin ≥ 3 months (basal-bolus therapy or only
             bolus insulin therapy)

          -  Current total daily insulin treatment <1.2 (I)U/kg/day

          -  Body Mass Index below or equal to 40.0 kg/m²

          -  HbA1c ≤ 9.0% by local laboratory analysis

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial products or related products

          -  Type 1 diabetes mellitus

          -  Previous participation in this trial

          -  The receipt of any investigational product within 60 days prior to this trial

          -  Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis
             screening tests, as judged by the Investigator considering the underlying disease

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea), as judged by the Investigator

          -  Presence of renal impairment (Estimated Glomerular filtration Rate (eGFR)<60
             milliliters/minute/1.73m²)

          -  Presence of late diabetic complications and/or acute coronary heart disease.

          -  Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion
             of the investigator might change gastrointestinal motility and food absorption

          -  Unusual meal habits and special diet requirements or unwillingness to eat the food
             provided in the trial

          -  Current treatment with corticosteroids
Clinical trial NCT02565628 (phase 1, status: completed)
Conditions: idiopathic parkinson's disease
ICD codes: G20
Drugs: pf-06669571, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have a clinical diagnosis of idiopathic Parkinson's disease and presence
             of at least 2 out of 3 cardinal characteristics (tremor, rigidity and/or
             bradykinesia).

          -  Must be Hoehn & Yahr Stage II-III inclusive and experiencing motor fluctuations in the
             form of end-of-dose wearing off during the morning hours or early morning akinesia.

          -  Subjects should be able to recognize their "wearing off" symptoms and verify that they
             usually improve after their next dose of Parkinson's disease medication. Subjects
             should be able to recognize drug-induced dyskinesias and verify whether or not they
             are troublesome.

        Exclusion Criteria:

        - History or clinical features consistent with an atypical parkinsonian syndrome, (for
        example: ataxia, dystonia, clinically significant orthostatic hypotension.
Clinical trial NCT02568280 (phase 1, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: faster-acting insulin aspart, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18-64 years (both inclusive) at the time of signing informed
             consent

          -  Subjects diagnosed (clinically) with type 1 diabetes mellitus at least 365 days prior
             to the day of screening

          -  Body mass index 18.5-28.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Smoker (defined as a subject who is smoking at least five cigarettes or the equivalent
             per day) who is not able or willing to refrain from smoking or use of nicotine gum or
             transdermal nicotine patches during the inpatient period

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to screening
Clinical trial NCT02572167 (phase 1/phase 2, status: active, not recruiting)
Conditions: hodgkin lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: brentuximab vedotin, nivolumab
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Relapsed or refractory Hodgkin lymphoma following failure of standard frontline
             chemotherapy for the treatment of classical Hodgkin lymphoma

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Previously treated with brentuximab vedotin, immune-oncology agents, or received an
             allogeneic or autologous stem cell transplant

          -  Documented history of a cerebral vascular event

          -  History of another invasive malignancy that has not been in remission for at least 3
             years

          -  History of progressive multifocal leukoencephalopathy (PML)
Clinical trial NCT02572687 (phase 1, status: completed)
Conditions: gastric cancer, gastroesophageal junction adenocarcinoma, non-small cell lung cancer, hepatocellular carcinoma
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: ramucirumab, medi4736
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Measurable metastatic disease or locally advanced and unresectable disease

               -  Has histopathologically confirmed gastric or GEJ adenocarcinoma with documented
                  disease progression after 1-2 prior lines of systemic therapy

               -  Has histopathologically confirmed nonsquamous or squamous NSCLC with documented
                  disease progression after 1-3 prior lines of systemic therapy

               -  Has histopathologically or cytologically confirmed HCC, Child-Pugh Class A, with
                  documented disease progression during or after discontinuation of sorafenib
                  therapy, or intolerance of sorafenib therapy, and an α-fetoprotein (AFP) ≥ 1.5x
                  upper limit of normal

          -  Availability of tumor tissue for biomarker analysis

          -  Has an Eastern Cooperative Oncology Group Performance Status of 0 or 1

          -  Has adequate organ function

        Exclusion Criteria:

          -  Has known brain metastases

          -  Has a history of prior cancers not included in this study that were either not treated
             with curative intent or have been active within the past 5 years

          -  History of allogeneic organ transplant

          -  Has active or prior documented autoimmune disease within the past 24 months

          -  Has human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome
             (AIDS)-related illness, or a history of immunodeficiency

          -  Has active hepatitis B or hepatitis C infection, or co-infection with both hepatitis B
             and C virus

          -  For gastric/GEJ and NSCLC participants, has chronic hepatitis B or hepatitis C
             infection. (For HCC participants, those with chronic hepatitis B virus [HBV] infection
             with a negative HBV deoxyribonucleic acid [DNA] test and who are on antiviral therapy,
             and those with chronic hepatitis C virus [HCV] infection are eligible)

          -  Has a history of interstitial lung disease, idiopathic pulmonary fibrosis,
             pneumoconiosis, non-infections pneumonitis, radiation-induced or drug-induced
             pneumonitis

          -  Has received any previous systemic therapy targeting programmed death (PD) 1 or
             PD-ligand 1/2 signaling pathways, and other immune checkpoint inhibitors

          -  Have received previous systemic therapy with ramucirumab
Clinical trial NCT02580695 (phase 1/phase 2, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: hyaluronic acid
SMILES: CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Symptomatic Knee OA, Kellgren and Lawrence grade I, II, III on plain Rx films.

          -  Chondromalacia patella grade I-III on knee MRI. With or without meniscal tear.

          -  Stable knee and normal clinical exam of involved extremity

          -  Written informed consent for patients.

        Exclusion Criteria:

          -  Bilateral symptomatic knee OA

          -  Local or systemic infection.

          -  Active neoplasia or immunosuppressive state

          -  Pregnancy or Breastfeeding

          -  Body Mass Index ≥ 30

          -  Presence of Pacemaker or Lower extremity metal implant

          -  Anticoagulant treatment other than aspirin.

          -  Recent use of oral (previous month) or intra-articular (previous 3 months)
             corticosteroids

          -  Concomitant inflammatory joint disease (cristal, connective tissue disease)

          -  Valgus (>10o) or Varus (>5o) deformity of involved extremity

          -  Condilar or Tibial plateau Generalized Bone Marrow edema on MRI

          -  Significant symptomatic hip or spine disease

          -  Significant abnormality in baseline lab tests
Clinical trial NCT02583373 (phase 1, status: completed)
Conditions: pneumonia, pneumococcal infections
ICD codes: A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, J12.0
Drugs: cal02 low-dose, cal02 high-dose, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult male or female patients ≥ 18 years and ≤ 80 years of age

          -  Body weight 40-140 kg

          -  Severe pneumonia caused by Streptococcus pneumoniae managed in an ICU

          -  CURB-65 score ≥ 3 in patients aged > 65 and CURB-65 ≥ 2 in patients aged < 65

          -  Streptococcus pneumoniae identification with the urine antigen test or any other
             proven documented identification method

          -  Written informed consent provided by the patient, the relatives or the designated
             trusted person and/or according to local guidelines

        Exclusion Criteria:

          -  Patients with hospital-acquired-, health care-acquired- or ventilator-
             associated-pneumonia

          -  More than (i) 12 hours since diagnosis of severe CAPP and (ii) 24 hours or 60 hours
             since antibiotic treatment IV or per os, respectively, unless documented not to be
             active against S. pneumoniae, will have elapsed at the time of IMP administration

          -  APACHE II score > 30 points

          -  SOFA score > 12 points

          -  Inability to maintain a mean arterial pressure ≥ 50 mm Hg

          -  Known hypersensitivity to liposomal formulations

          -  Patients with severe neutropenia or lymphoma or current or anticipated chemotherapy

          -  End-stage neuromuscular disorders

          -  Patients who have long-term tracheostomy

          -  Current or recent participation in an investigational study

          -  Presence of other pneumococcal site infection

          -  Patients with known acquired immune deficiency syndrome (AIDS) with CD4 count < 200
             cells/mL

          -  Patients with known post-obstructive pneumonia (active primary lung cancer or another
             malignancy metastatic to the lungs)

          -  Patients with cystic fibrosis, Pneumocystis jiroveci pneumonia, or active tuberculosis

          -  Patients receiving immunosuppressant therapy

          -  Patients with a known liver function deficiency

          -  Splenectomised patients

          -  Patients who have experienced an allergic reaction to eggs

          -  Moribund clinical condition

          -  Nursing and pregnant women

          -  Women of child bearing potential not using an effective contraception.
Clinical trial NCT02587741 (early phase 1, status: recruiting)
Conditions: diabetic retinopathy
ICD codes: H35.23, H35.20, H35.21, H35.22, E10.3553, E11.3553, E13.3553
Drugs: metformin, lantus, novomix30
SMILES: CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          1. aged 30-65;

          2. diagnosed to be type 2 diabetes in accordance with the WHO diagnostic criteria in 1999
             .

          3. diabetes duration for 5 years or less;

          4. the glycosylated hemoglobin (HbA1c) is higher than or equal to7.0% ;

          5. body mass index (BMI) 20-35 kg/m2;

          6. fluorescein fundus angiography (FFA) showed no diabetic retinopathy;

          7. women of childbearing-age have birth control plan for 5 years plan;

        Exclusion Criteria:

          1. pregnant or lactating women;

          2. diabetes autoantibodies (GAD) antibodies positive;

          3. occurred state of diabetic ketoacidosis, diabetes, high permeability, diabetes lactic
             acidosis within a half years ;

          4. aspartate aminotransferase (AST), alanine aminotransferase (ALT) 2.5 times higher than
             normal ceiling, and/or serum creatinine (Cr) or 133 umol/l (1.5 mg/dl);

          5. hemoglobin disease history which can affect determination of HbA1c;

          6. have received a coronary angioplasty, coronary artery stent implantation, coronary
             artery bypass surgery, there was myocardial infarction, unstable angina, and clinical
             significance of abnormal ecg, cerebrovascular accident, or transient ischemic attack.

          7. psychiatric patients;

          8. any eye eyesight < 0.1 patients (WHO blind eye disease: keratitis, need serious
             cataract surgery, glaucoma, uveitis, high myopia shaft > 26.5 mm, history of ocular
             trauma;Other ophthalmology medical history: the central vein occlusion, branch vein
             occlusion, wet sex senile macular degeneration, etc.;

          9. in eye surgery history, history of cataract surgery, and three months; Other serious
             diseases, the researchers think that don't fit into the patients